


**Amendments to the Claims**

Please amend Claims 35, 56 and 57. The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**


1-33. (Canceled)

34. (Previously Presented) A method of treating a subject with a multi-drug resistant leukemia, said method comprising administering to the subject an effective amount of a compound represented by the following structural formula:



or a pharmaceutically acceptable salt thereof.


35. (Currently Amended) A method of treating a human subject with leukemia, said method comprising administering to the subject an effective amount of a compound represented by the following structural formula:



or a pharmaceutically acceptable salt thereof, wherein the subject compound is ~~optionally co-administered~~ administered alone or in combination with an effective amount of a second anti-cancer agent other than paclitaxel or a paclitaxel analog.


36-50. (Canceled)

51. (Previously Presented) The method of Claim 34, wherein the method further comprises administering to the subject an effective amount of paclitaxel or docetaxol.
52. (Previously Presented) A method of treating a subject with a multi-drug resistant uterine sarcoma, said method comprising administering to the subject an effective amount of a compound represented by the following structural formula:




or a pharmaceutically acceptable salt thereof.

53. (Previously Presented) The method of Claim 52, wherein the method further comprises administering to the subject an effective amount of paclitaxel or docetaxol.
54. (Previously Presented) A method of treating a subject with a multi-drug resistant melanoma, said method comprising administering to the subject an effective amount of a compound represented by the following structural formula:




or a pharmaceutically acceptable salt thereof.

55. (Previously Presented) The method of Claim 54, wherein the method further comprises administering to the subject an effective amount of paclitaxel or docetaxol.
56. (Currently Amended) A method of treating a human subject with uterine sarcoma, said method comprising administering to the subject an effective amount of a compound represented by the following structural formula:



or a pharmaceutically acceptable salt thereof, wherein the ~~subject compound~~ is ~~optionally~~  
~~co-administered~~ administered alone or in combination with an effective amount of a  
second anti-cancer agent other than paclitaxel or a paclitaxel analog.

57. (Currently Amended) A method of treating a human subject with melanoma, said method comprising administering to the subject an effective amount of a compound represented by the following structural formula:



or a pharmaceutically acceptable salt thereof, wherein the ~~subject compound~~ is ~~optionally~~  
~~co-administered~~ administered alone or in combination with an effective amount of a  
second anti-cancer agent other than paclitaxel or a paclitaxel analog.